vs
Side-by-side financial comparison of AGIOS PHARMACEUTICALS, INC. (AGIO) and Cheche Group Inc. (CCG). Click either name above to swap in a different company.
Cheche Group Inc. is the larger business by last-quarter revenue ($32.8M vs $20.0M, roughly 1.6× AGIOS PHARMACEUTICALS, INC.). Cheche Group Inc. runs the higher net margin — 0.5% vs -541.1%, a 541.6% gap on every dollar of revenue.
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013.
Cheche Group Inc. is a leading automotive digital service provider headquartered in China. It offers integrated solutions including auto insurance intermediary services, smart auto after-sales support, and connected vehicle technology products, serving individual car owners, auto dealerships, and insurance partners across domestic and select Southeast Asian markets.
AGIO vs CCG — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $20.0M | $32.8M |
| Net Profit | $-108.0M | $153.6K |
| Gross Margin | 90.6% | 5.7% |
| Operating Margin | -608.9% | — |
| Net Margin | -541.1% | 0.5% |
| Revenue YoY | 86.1% | — |
| Net Profit YoY | -11.9% | — |
| EPS (diluted) | $-1.86 | $0.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $32.8M | ||
| Q4 25 | $20.0M | — | ||
| Q3 25 | $12.9M | — | ||
| Q2 25 | $12.5M | $26.0M | ||
| Q1 25 | $8.7M | — | ||
| Q4 24 | $10.7M | $18.6M | ||
| Q3 24 | $9.0M | — | ||
| Q2 24 | $8.6M | $36.1M |
| Q1 26 | — | $153.6K | ||
| Q4 25 | $-108.0M | — | ||
| Q3 25 | $-103.4M | — | ||
| Q2 25 | $-112.0M | $-492.4K | ||
| Q1 25 | $-89.3M | — | ||
| Q4 24 | $-96.5M | $-196.7K | ||
| Q3 24 | $947.9M | — | ||
| Q2 24 | $-96.1M | $-7.6M |
| Q1 26 | — | 5.7% | ||
| Q4 25 | 90.6% | — | ||
| Q3 25 | 87.0% | — | ||
| Q2 25 | 86.3% | 4.9% | ||
| Q1 25 | 87.6% | — | ||
| Q4 24 | 88.3% | 5.2% | ||
| Q3 24 | 91.3% | — | ||
| Q2 24 | 82.6% | 4.3% |
| Q1 26 | — | — | ||
| Q4 25 | -608.9% | — | ||
| Q3 25 | -907.4% | — | ||
| Q2 25 | -1020.1% | -2.0% | ||
| Q1 25 | -1222.0% | — | ||
| Q4 24 | -1165.3% | -0.3% | ||
| Q3 24 | -1146.9% | — | ||
| Q2 24 | -1228.3% | -4.7% |
| Q1 26 | — | 0.5% | ||
| Q4 25 | -541.1% | — | ||
| Q3 25 | -803.1% | — | ||
| Q2 25 | -899.4% | -1.9% | ||
| Q1 25 | -1023.3% | — | ||
| Q4 24 | -899.6% | -1.1% | ||
| Q3 24 | 10574.7% | — | ||
| Q2 24 | -1115.7% | -21.0% |
| Q1 26 | — | $0.00 | ||
| Q4 25 | $-1.86 | — | ||
| Q3 25 | $-1.78 | — | ||
| Q2 25 | $-1.93 | $-0.01 | ||
| Q1 25 | $-1.55 | — | ||
| Q4 24 | $-1.44 | $-0.00 | ||
| Q3 24 | $16.22 | — | ||
| Q2 24 | $-1.69 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.1M | $20.0M |
| Total DebtLower is stronger | — | $193.3K |
| Stockholders' EquityBook value | $1.2B | — |
| Total Assets | $1.3B | $203.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $20.0M | ||
| Q4 25 | $89.1M | — | ||
| Q3 25 | $92.7M | — | ||
| Q2 25 | $80.9M | $23.1M | ||
| Q1 25 | $79.0M | — | ||
| Q4 24 | $76.2M | $21.1M | ||
| Q3 24 | $253.7M | — | ||
| Q2 24 | $84.5M | $28.2M |
| Q1 26 | — | $193.3K | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $690.0K | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.3B | — | ||
| Q2 25 | $1.4B | $47.1M | ||
| Q1 25 | $1.5B | — | ||
| Q4 24 | $1.5B | $49.1M | ||
| Q3 24 | $1.6B | — | ||
| Q2 24 | $660.5M | $48.6M |
| Q1 26 | — | $203.5M | ||
| Q4 25 | $1.3B | — | ||
| Q3 25 | $1.4B | — | ||
| Q2 25 | $1.5B | $177.3M | ||
| Q1 25 | $1.6B | — | ||
| Q4 24 | $1.7B | $177.7M | ||
| Q3 24 | $1.8B | — | ||
| Q2 24 | $773.1M | $139.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.01× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-96.2M | — |
| Free Cash FlowOCF − Capex | $-97.3M | — |
| FCF MarginFCF / Revenue | -487.5% | — |
| Capex IntensityCapex / Revenue | 5.6% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-377.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-96.2M | — | ||
| Q3 25 | $-88.2M | — | ||
| Q2 25 | $-77.1M | $-44.7M | ||
| Q1 25 | $-111.5M | — | ||
| Q4 24 | $-133.2M | $-15.8M | ||
| Q3 24 | $-84.2M | — | ||
| Q2 24 | $-72.6M | $-1.0K |
| Q1 26 | — | — | ||
| Q4 25 | $-97.3M | — | ||
| Q3 25 | $-89.7M | — | ||
| Q2 25 | $-78.0M | — | ||
| Q1 25 | $-112.3M | — | ||
| Q4 24 | $-134.1M | $-16.0M | ||
| Q3 24 | $-84.6M | — | ||
| Q2 24 | $-72.7M | $-1.1K |
| Q1 26 | — | — | ||
| Q4 25 | -487.5% | — | ||
| Q3 25 | -696.5% | — | ||
| Q2 25 | -626.2% | — | ||
| Q1 25 | -1286.4% | — | ||
| Q4 24 | -1250.1% | -85.9% | ||
| Q3 24 | -944.2% | — | ||
| Q2 24 | -844.4% | -0.0% |
| Q1 26 | — | — | ||
| Q4 25 | 5.6% | — | ||
| Q3 25 | 12.1% | — | ||
| Q2 25 | 7.0% | — | ||
| Q1 25 | 8.8% | — | ||
| Q4 24 | 9.0% | 1.2% | ||
| Q3 24 | 4.7% | — | ||
| Q2 24 | 1.8% | 0.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -0.09× | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
